Search

Displaying results 1421 - 1430 of 2454 in total
  1. Drug

    Desmethylsertraline

    go.drugbank.com/drugs/DB14071
    Experimental

    Desmethylsertraline is a metabolite of sertraline.

    Categories: P-glycoprotein inhibitors
  2. Drug

    Reversin 121

    go.drugbank.com/drugs/DB14072
    Experimental

    Reversin 121 is a hydrophobic peptide chemosensitizer that can reverse P-glycoprotein-mediated multidrug resistance.

    Categories: P-glycoprotein inhibitors
  3. Drug

    Polysorbate 60

    go.drugbank.com/drugs/DB14153
    Investigational

    Categories: P-glycoprotein inhibitors
  4. Drug

    Sarafloxacin

    go.drugbank.com/drugs/DB11491
    ApprovedVet approvedWithdrawn

    Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  5. Drug

    Salinomycin

    go.drugbank.com/drugs/DB11544
    ExperimentalVet approved

    Categories: P-glycoprotein inhibitors
  6. Drug

    Lesinurad

    go.drugbank.com/drugs/DB11560
    ApprovedWithdrawn

    Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptak...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  7. Drug

    Insulin tregopil

    go.drugbank.com/drugs/DB11568
    Investigational

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  8. Drug

    Rupatadine

    go.drugbank.com/drugs/DB11614
    ApprovedInvestigational

    Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesProducts: RUPATADINA DOC GENERICI
  9. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    Tucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tuca...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  10. Drug

    Bryostatin 1

    go.drugbank.com/drugs/DB11752
    Investigational

    Bryostatin 1 has been investigated for the treatment of HIV Infection and Alzheimer's Disease.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors